Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Empowering Compassionate Care: Elevating the Role of the Palliative Care Registered Nurse
Valinski, Sarah, Wild, Ellen, Metzger, Abbey, Cutshall, Susanne, Wild, Ellen, Metzger, Abbey K., Cutshall, Susanne M.

Mayo Clinic

Journal of Hospice & Palliative Nursing | May 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/njh.0000000000001235 | PMID 42212924 Get It

Over the past 2 decades, the landscape of serious illness has changed dramatically, with patients living longer and undergoing prolonged treatment. This has increased the need for specialty palliative care (PC) in both inpatient and outpatient settings. Specialty PC teams are interprofessional, composed of diverse healthcare professionals who collaborate seamlessly to provide whole-person care. The palliative care registered nurse plays a pivotal role on the PC team by enhancing communication, holistic compassionate care, and expert care coordination. This article explores the multifaceted specialty palliative care registered nurse role, providing examples of how this role can be used to expand the reach of PC. Specific examples include the expansion of the registered nurse role on an interprofessional PC team to deliver integrative nursing interventions and opportunities for ongoing professional development to meet the complex needs of patients and families impacted by serious illness.
Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
Wechalekar, Ashutosh , Sanchorawala, Vaishali , Zepeda, Victor H. Jimenez-, Suzuki, Kenshi, Lentzsch, Suzanne , Huart, Antoine , Carpinteiro, Alexander , Swenson, Eugene , Khan, Zilehuma, Catini, Julia, Kulkarni, Hrishikesh, Meltzer, Brian, Lake, Stephen, Liedtke, Michaela , Investigators, for the CARES, Ting, Stephen Bek Ngie, Mollee, Peter Norman, Meuleman, Nathalie, Delforge, Michel, Zepeda, Victor Jimenez, Zhang, Shuyang, Du, Xin, Wang, Jianan, Qian, Honglan, Sun, Chunyan, Belhadj, Karim , Arnulf, Bertrand, Karlin, Lionel, Macro, Margaret, Colella, Jean-Marc Schiano De, Stoppa, Anne-Marie, Viallard, Jean-Francois, Fenk, Roland, Hansen, Timon, Girke, Vera, Nogai, Axel, Gatt, Moshe, Lavi, Noa, Magen, Hila , Palladini, Giovanni, Pane, Fabrizio, Buda, Gabriele , Ishida, Tadao, Iida, Shinsuke, Jamroziak, Krzysztof, Byun, Jamin, Koh, Youngil, Kim, Kihyun, Villamediana, Ramón Lecumberri, Lopez, Maria Teresa Cibeira, Martínez, Irene Romera, Duarte, Rafael , Castello, Isabel Angela Krsnik, Garcia, Maria Esther Gonzalez , Chacon, Eusebio Narciso Martin, Martínez, Javier Alberto Rojas , Valent, Jason , Rosenzweig, Michael A., Chung, Alfred, Wong, Sandy, Bumma, Naresh , Comenzo, Raymond, Gaballa, Mahmoud, Lee, Hans C., Kaufman, Gregory P., Passero, Frank, Stockerl-Goldstein, Keith, Waxman, Adam, D'Souza, Anita, Cowan, Andrew, Lee, Sarah, Libby, Edward, Godara, Amandeep , Kovacsovics, Tibor, Sengsayadeth, Salyka, Goodman, Stacey , Chaulagain, Chakra, Wechalekar, Ashutosh D. , Dispenzieri, Angela , Sanchorawala, Vaishali , Kastritis, Efstathios , Lentzsch, Suzanne , Meltzer, Brian , Liedtke, Michaela , Dispenzieri, Angela , Kastritis, Efstathios , Bhutani, Divaya , Bianchi, Giada , Suzuki, Kenshi , Khan, Zilehuma, Kulkarni, Hrishikesh, Lake, Stephen, Ting, Stephen B. , Mollee, Peter , Agis, Hermine , Straßl, Irene , Meuleman, Nathalie , Delforge, Michel , Sedlák, František , Jaccard, Arnaud , Arnulf, Bertrand , Karlin, Lionel , Macro, Margaret , Stoppa, Anne‐Marie, Bridoux, Frank , Chalopin, Thomas , Viallard, Jean‐François , Fenk, Roland , Symeonidis, Argiris , Annibali, Ombretta , Iida, Shinsuke, Ikezoe, Takayuki , Jamroziak, Krzysztof , Koh, Youngil, López, Maria Teresa Cibeira, Rios, Rafael, Garcia, Maria Esther Gonzalez, Chacón, Eusebio Martín, Valent, Jason Neil , Rosenzweig, Michael, Comenzo, Raymond L. , Gaballa, Mahmoud , Kaufman, Gregory P., Medvedova, Eva , Passero, Frank Charles , Stockerl-Goldstein, Keith , Chaulagain, Chakra P.

Mayo Clinic

Journal of Clinical Oncology | May 29, 2026 | Volume: 44 | Issue: 20 | Pages: 1899-1910

10.1200/jco-26-00755 | PMID 42212672 Get It

PURPOSE In immunoglobulin light chain (AL) amyloidosis, amyloid fibrils cause organ dysfunction. Anselamimab, a monoclonal antibody, selectively binds to amyloid fibrils, accelerating their clearance. METHODS Newly diagnosed patients with European modification of Mayo 2004 stage IIIa or IIIb AL amyloidosis were randomly assigned to receive anselamimab or placebo with cyclophosphamide, bortezomib, and dexamethasone (with or without daratumumab). The primary end point was a hierarchical composite of time to all-cause mortality (ACM) and frequency of cardiovascular hospitalizations (CVHs), analyzed using the Finkelstein-Schoenfeld test and win ratio estimation. RESULTS Among 406 randomly assigned patients, the primary end point win ratio for anselamimab versus placebo was 1.11 (95% CI, 0.83, 1.50; P = .332) and the hazard ratio (HR) for ACM was 0.80 (95% CI, 0.57, 1.13; P = .290). CVH rates in the anselamimab and placebo groups were 0.59 (95% CI, 0.42, 0.83) and 0.89 (95% CI, 0.55, 1.43), respectively ( P = .145). Among patients with kappa isotype (n = 72), the win ratio was 2.06 (95% CI, 0.98, 4.31; P = .100) and anselamimab reduced ACM by 62% versus placebo (HR, 0.38; 95% CI, 0.17 to 0.86; nominal P = .012), and CVH by 71% (IRR, 0.29; 95% CI, 0.10 to 0.87; nominal P = .028) with improvements in Kansas City Cardiomyopathy Questionnaire-Overall Score. There was no clinical benefit observed in the lambda population. Anselamimab was generally well-tolerated; safety data were comparable between treatment arms overall. CONCLUSION Treatment with anselamimab, an antifibril antibody used alongside antiplasma cell dyscrasia therapy, while not meeting the primary end point in the overall population, significantly improved ACM and CVH in patients with kappa AL, potentially offering a new therapeutic option for this isotype.
Dose-dependent white matter changes associated with repetitive head impacts in former American football players
Arciniega, Hector , Wickham, Alana, Szekely, Brian, Kim, Nicholas, Cho, Kang I, Carrington, Holly, Knyazhanskaya, Evdokiya , John, Omar , Jung, Leonard , Breedlove, Katherine M. , Mirmajlesi, Anya S, Stearns, Jared, Rushmore, R Jarrett, Daneshvar, Daniel H, Wiegand, Tim L T, Billah, Tashrif , Pasternak, Ofer, Cetin-Karayumak, Suheyla, Rathi, Yogesh, Coleman, Michael J, Bernick, Charles, Balcer, Laura J, Im, Brian , Datta, Shae , Alosco, Michael L. , Lin, Alexander P, Cummings, Jeffrey L, Reiman, Eric M, Stern, Robert A, Shenton, Martha E, Bouix, Sylvain, Su, Yi, Chen, Kewei, Protas, Hillary, Boker, Connie, Au, Rhoda, Cantu, Robert C, Farrer, Lindsay, Helm, Robert, Katz, Douglas I, Kowall, Neil, Mez, Jesse, Mercier, Gustavo, Otis, James, Weller, Jason, Simkin, Irene, Andino, Alondra, Conneely, Shannon, Diamond, Courtney, Fagle, Tessa, Haller, Olivia, Hunt, Tennyson, Gullotti, Nicole, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen, Nanna, Mary, Platt, Taylor, Rice, Fiona, Sestak, Madison, McClean, Michael, Tripodis, Yorghos, Annis, Douglas, Chaisson, Christine, Dixon, Diane, Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Lu, Jun, Martin, Brett, Ojo, Emmanuel, Palmisano, Joseph N, Pine, Brittany, Ramachandran, Janani, Fitzsimmons, Jennifer, Arcinieago, Hector, Bonke, Elena, Coello, Eduardo , Jung, Leonhard, Liao, Huijun, Loy, Maria, Rizzoni, Elizabeth, Schultz, Vivian , Silva, Annelise, Vessey, Brynn, Banks, Sarah, Miller, Jason, Ritter, Aaron , Sabbagh, Marwan, Cruz, Raelynn de la, Durant, Jan, Golceker, Morgan, Harmon, Nicolette, Kaylegian, Kaeson, Long, Rachelle, Nance, Christin, Sandoval, Priscilla, Serrano, Andrew, Dodick, David W, Geda, Yonas, Wethe, Jennifer V, Falk, Bryce, Duffy, Amy, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Bellgowan, Patrick, Balcer, Laura, Barr, William, GOLDBERG, JUDITH, Wisniewski, Thomas, Kirov, Ivan, Lui, Yvonne, Marmar, Charles, Hasanaj, Lisena, Serrano, Liliana , Al-Kharafi, Alhassan, George, Allan, Martin, Sammie, Riley, Edward, Runge, William, Peskind, Elaine R. , Colasurdo, Elizabeth , Marcus, Daniel S, Gurney, Jenny , Greenwald, Richard, Johnson, Keith A, Wethe, Jennifer V. , Wiegand, Tim L. T. , Jung, Leonard B , Breedlove, Katherine , Stearns, Jared , Adler, C H , Alosco, Michael L , Koerte, Inga K , Wethe, Jennifer V , Arciniega, Hector , Kim, Nicholas , Carrington, Holly , Rushmore, R. Jarrett , Daneshvar, Daniel H. , Pasternak, Ofer , Karayumak, Suheyla Cetin , Rathi, Yogesh , Coleman, Michael J. , Adler, Charles H. , Bernick, Charles , Balcer, Laura J. , Reiman, Eric M. , Shenton, Martha E. , Bouix, Sylvain , Protas, Hillary , Cantu, Robert C. , Katz, Douglas I. , Mez, Jesse , Weller, Jason , Fagle, Tessa, Mariani, Megan, McLaughlin, Kathleen , Pulukuri, Surya Vamsi , Sestak, Madison, McClean, Michael D , Tripodis, Yorghos , Annis, Douglas, Finney, Carolyn, Palmisano, Joseph , Pine, Brittany, Ramachandran, Janani , Bonke, Elena M. , Liao, Huijun, II, Robert W. Turner , Marek, Kenneth , Dodick, David W. , Geda, Yonas E. , Howard, Marci, Montague, Michelle, Babcock, Debra, Bellgowan, Patrick S.F. , Barr, William , Kirov, Ivan, George, Allan, Colasurdo, Elizabeth A. , Marcus, Daniel S., Johnson, Keith A.

Mayo Clinic

Brain Communications | May 29, 2026 | Volume: 8 | Issue: 3 | Pages: No page available

10.1093/braincomms/fcag195 | PMID 42293319 Get It

Abstract Repetitive head impacts sustained during American football have been associated with neuropathological changes such as white matter shear injuries. However, the impact of specific factors, such as age of first exposure and cumulative head impact burden, on white matter integrity remains unclear. This study investigated in vivo white matter microstructural changes using diffusion tensor imaging and tract-based spatial statistics in 165 male former American football players (mean age 57.3 years, range 45–74) and 52 unexposed asymptomatic male controls (mean age 59.4 years, range 45–74) in the DIAGNOSE CTE Research Project. Compared to controls, former football players exhibited significantly higher fractional anisotropy (FA) in 1.97% of the white matter skeleton (1552 voxels; Cohen’s d = 0.587) and higher tissue-corrected FA (FAt) in 1.48% of the white matter skeleton (1004 voxels; Cohen’s d = 0.616). No significant differences were observed for mean diffusivity, axial diffusivity, radial diffusivity, or free water between football players and controls. Among football players, there were no significant differences in the white matter microstructure between players diagnosed with traumatic encephalopathy syndrome and those without the diagnosis. Lower FA was significantly associated with older age (P < 0.00001) and an earlier age of first exposure to tackle football (P < 0.01), while lower FAt was associated with greater cumulative head impact burden, specifically higher linear acceleration (P < 0.04) and rotational force (P < 0.02). This study highlights the influential role of exposure factors on white matter microstructure in former American football players, as well as the utility of diffusion tensor imaging to aid in characterizing the long-term effects of repetitive head impacts in contact sport athletes.
A phase 2 clinical trial in progress of (Z)-endoxifen plus goserelin as neoadjuvant therapy in premenopausal women with ER+/HER2– breast cancer (EVANGELINE).
Quay, Steven, ERICKSON, Hayley, Mina, Lida A. , Advani, Pooja , Leon‐Ferre, Roberto A. , Giridhar, Karthik, Flora, Daniel , Jones, Jason M. , Burhow, Sarah, Abramson, Vandana G., Irvin, William Johnson, Ehsani, Sima, Al-Jazayrly, Ghassan, Goetz, M. P., Quay, Steven C. , Suman, Vera J. , Bagegni, Nusayba , Ingle, James N. , Boughey, Judy C. , Burhow, Sarah A., Reid, Joel M. , Abramson, Vandana G. , Irvin, WJ, Khan, Seema A. , Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps655 Get It

TPS655 Background: Early (14-28 day) on-treatment suppression of tumor proliferation during neoadjuvant endocrine therapy (NET) is strongly associated with favorable long-term outcomes in estrogen receptor–positive (ER+) HER2– breast cancer. In premenopausal women, tamoxifen with or without ovarian function suppression (OFS) results in suboptimal Ki-67 suppression compared with aromatase inhibitor + OFS. (Z)-endoxifen (ENDX), the active metabolite of tamoxifen, dually inhibits ER signaling and PKCβ1-mediated AKT activation, supporting its evaluation as an alternative NET strategy in this population. Methods: EVANGELINE (NCT05607004) is an ongoing, multicenter, open-label Phase 2 study evaluating daily 40 mg ENDX plus goserelin administered every 28 days as neoadjuvant therapy in premenopausal women with ER+/HER2–, cT2–3, cN0–1 breast cancer. The primary objective is to determine the proportion of patients with baseline Ki-67 >10% who achieve Ki-67 ≤10% after 4 weeks of therapy. A Simon two-stage design is used to test whether the Week 4 Ki-67 ≤10% rate is at least 65%, with 20 patients enrolled into the first stage and, if promising, another 25 patients enrolled into the second stage (cohort A). A parallel cohort of 20 patients with baseline Ki-67 ≤10% (cohort B) is enrolled to assess objective response rate (ORR) at 24 weeks per RECIST v1.1. Secondary objectives include examining safety and tolerability, residual cancer burden, and PEPI score. Correlative analyses include examining effect of treatment on select tumor and plasma biomarkers. Clinical trial information: NCT05607004 .
TROPION-Urothelial03: A phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy (CT) vs gemcitabine + platinum CT in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) with progression on or after enfortumab
Galsky, Matthew D., Drakaki, Alexandra, Basu, Arnab, Bedke, Jens, Loriot, Y, Kikuchi, Eiji, Guo, J Z , Garmezy, Benjamin, Sridhar, Srikala S., Klauss, G., Lin, Daisy, Liu, Chelsea, Powles, Thomas, Galsky, Matthew D. , Drakaki, Alexandra , McGregor, Bradley A. , Bedke, Jens , Loriot, Yohann , Sridhar, Srikala S , Liu, Chelsea, Apolo, Andrea B , Powles, Thomas

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps4642 Get It

TPS4642 Background: Although first-line (1L) EV + pembrolizumab has improved outcomes for patients with la/mUC, most experience disease progression, highlighting an unmet need for novel therapies. TROP2 is a glycoprotein highly expressed in several epithelial tumors, including UC. Dato-DXd is a TROP2-directed antibody–drug conjugate comprising an anti-TROP2 monoclonal antibody, a tetrapeptide-based cleavable linker, and a topoisomerase I inhibitor payload (DXd), designed to induce selective tumor-cell death and reduce systemic exposure to the payload. Dato-DXd has demonstrated durable efficacy and a manageable safety profile in patients with la/mUC both as monotherapy (TROPION-PanTumor01 [NCT03401385]) and in combination with immunotherapy (TROPION-PanTumor03 [NCT05489211]). We describe a Phase 2/3 trial comparing the efficacy and safety of Dato-DXd + platinum CT (carboplatin or cisplatin) vs gemcitabine + platinum CT in participants with la/mUC with disease progression on or after EV + pembrolizumab. Methods: TROPION-Urothelial03 (NCT07129993) is a global, multicenter, randomized, open-label, Phase 2/3 trial. In Part A (Phase 2), ~60 participants will be randomized 1:1 to receive Dato-DXd 4 or 6 mg/kg + platinum CT. In Part B (Phase 3), ~570 participants will be randomized 1:1 to receive Dato-DXd at the recommended Phase 3 dose (determined using Part A data) + platinum CT vs gemcitabine + platinum CT. Randomization in Part A is stratified by assignment of platinum CT (carboplatin vs cisplatin), and in Part B, by assignment of platinum CT, presence vs absence of liver metastasis at screening, and time to progression on 1L EV + pembrolizumab (<6 vs ≥6 months). Study treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, death, loss to follow-up, or other reasons per protocol. Radiographic tumor assessments occur every 6 weeks for 54 weeks, then every 12 weeks. The primary endpoint of Part A is objective response rate (ORR) by investigator per Response Evaluation Criteria in Solid Tumours, version 1.1 (RECIST 1.1). The dual primary endpoints of Part B are progression-free survival (PFS) by blinded independent central review (BICR) per RECIST 1.1 and overall survival (OS). Secondary endpoints include duration of response by investigator per RECIST 1.1 (Part A), and PFS by investigator per RECIST 1.1 and ORR by BICR and investigator per RECIST 1.1 (Part B). In Part A, ORR will be summarized with 2-sided 95% exact confidence intervals using the Clopper–Pearson method by trial group. In Part B, PFS and OS will be compared between trial groups using a log-rank test stratified by randomization stratification factors, with hazard ratios from the stratified Cox regression model. Clinical trial information: NCT07129993 .
STELLA: A dose expansion of the ATR kinase inhibitor alnodesertib (ART0380) administered orally in combination with low-dose irinotecan to patients with advanced or metastatic CRC and PDAC.
Reiss, Kim Anna, Henry, Jason T. , Pelster, Meredith, Paulson, Andrew Scott , Headley, Desirée, Falcon, Susana Barriga, Millward, Helen, Fielding, Amelia, Menon, Suraj , Little, Nicola, Wilby, Alison, Smith, Graeme, Smith, Ian C., Bashir, Babar , Ulahannan, Susanna Varkey , Pedersen, Katrina S. , Pelster, Meredith S. , Barriga, Susana, Wilby, Alison

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps3184 Get It

TPS3184 Background: Replication stress (RS) creates cancer cell vulnerability to which the critical DNA damage response kinase, ATR (Ataxia-Telangiectasia and Rad3-related) responds. ATR senses the stress, halts the cell cycle, and promotes DNA repair to allow proliferation. Alnodesertib is an ATR inhibitor developed to prevent cancer cells from successfully repairing RS and proliferating further. In earlier stages of alnodesertib development, preclinical and translational research demonstrated that tumor cells experience three combined biological insults: irinotecan-induced RS, endogenous RS via ataxia-telangiectasia mutated (ATM) loss, and RS rescue prevention by ATR inhibition. Data from the dose escalation and initial dose expansion cohorts of this trial in a tumor agnostic population showed encouraging results in ATM-negative cancers (confirmed Overall Response Rate of 50% in 20 patients with ATM negative cancers and responses across 8 cancer types including complete responses, Ulahannan et al, AACR 2025). Tumor-specific dose expansion cohorts are now enrolling, including colorectal cancer (CRC) and pancreas ductal adenocarcinoma (PDAC). Methods: Two tumor-specific cohorts are now open, each enrolling approximately 50 patients (pts): ATM-negative CRC and ATM-negative PDAC. Pts will receive the recommended dose of alnodesertib 200mg orally on days 1-3 and 8-10 combined with low-dose irinotecan 60mg/m 2 IV on days 1 and 8, of each 21-day cycle. Tumor tissue is prescreened by immunohistochemistry for ATM protein loss (H score 0) for enrollment eligibility. Pts with CRC must have received a maximum of 2 prior chemotherapies excluding prior trifluridine/tipiracil, fruquintinib, or regorafenib, and pts with PDAC must have received a maximum of 1 prior chemotherapy for advanced disease. Prior targeted agents are allowed and do not count as prior lines of therapy. Key objectives include safety, tolerability, and preliminary efficacy. Clinical trial information: NCT04657068 .
IDE892 as monotherapy and in combination with IDE397 in patients with 5-methylthioadenosine phosphorylase-deleted ( MTAP -Del) advanced solid tumors (IDE892001): Phase 1 trial.
Garmezy, Benjamin, Herzberg, Benjamin, Devarakonda, Siddhartha, Parikh, K, Zarrabi, Kevin , Song, Michael M., Xiong, Henry Q., Sahebjam, Solmaz , Graef, Thorsten, Sachdev, Jasgit C. , Beaupre, Darrin M., Ahnert, Jordi Rodon, Herzberg, Benjamin, Devarakonda, Siddhartha, Salkeni, Mohamad Adham , Segar, Jennifer , Liu, Emily L. , Graef, Thorsten

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps3182 Get It

TPS3182 Background: MTAP deletion in solid tumors causes intracellular accumulation of methylthioadenosine (MTA) which partially inhibits activity of the key methylating enzyme, protein arginine methyltransferase 5 (PRMT5) and creates synthetic lethal dependencies on PRMT5 and methionine adenosyltransferase 2A (MAT2A), the rate limiting step in the synthesis of PRMT5 substrate, S-adenosyl methionine. PRMT5 and MAT2A are essential to transcription modulation, gene splicing, and DNA damage response. IDE892 is an MTA-cooperative PRMT5 inhibitor designed to exploit this vulnerability in MTAPdel tumors. Preclinical studies report robust antitumor activity with IDE892 monotherapy in MTAPdel xenograft models and an enhanced response when combined with IDE397 (an allosteric MAT2A inhibitor). IDE892-001 is a Phase 1 study evaluating safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IDE892 alone and in combination with IDE397. Methods: IDE892-001 is an ongoing, open-label, multicenter four-part study: IDE892 monotherapy dose escalation (Part 1), monotherapy dose expansion in MTAPdel NSCLC (Part 2), IDE892 + IDE397 dose escalation (Part 3), and combination expansion in MTAPdel NSCLC (Part 4). Adults with advanced or metastatic MTAPdel solid tumors including lung, urothelial, gastrointestinal cancers (including pancreatic and biliary tract cancers) and mesothelioma are eligible following disease progression on standard therapies. Key exclusion criteria include symptomatic brain metastases, cardiac disease, active severe infection, and prior treatment with a PRMT5 or MAT2A inhibitor. Part 1 uses a Bayesian optimal interval design to determine maximum tolerated dose (MTD) and recommended doses for expansion (RDE). Part 3 uses a modified toxicity probability interval design to evaluate escalating combinations of IDE892 and IDE397. Oral treatment is given QD in 21-day cycles until progression or unacceptable toxicity. Serial blood samples are collected for PD analyses. Imaging will be performed every 6 weeks through week 24, then every 9–12 weeks. Efficacy endpoints will be assessed by RECIST v1.1. Primary objectives for dose-escalation cohorts (Parts 1 and 3) are safety and tolerability, including determination of MTD/RDE. In expansion cohorts (Parts 2 and 4), co-primary objectives include safety and preliminary antitumor activity (objective response rate and duration of response). Secondary endpoints for all parts include PK of IDE892 alone and in combination with IDE397. Exploratory assessments include progression free survival, changes in circulating and tumor-based markers of PRMT5 pathway modulation, molecular predictors of response, exposure–response relationships, and metabolite characterization. Clinical trial information: NCT07277413 .
A single-arm, phase II study of sequential therapy with curative intent in de novo HER2+ metastatic breast cancer: The SAPPHO study.
Ruddy, Kathryn Jean, Heiling, Hillary, Rozenblit, Mariya, Dees, Elizabeth Claire , Frey, Anna , Ossing, Sarah, Koegel, Susan, LaScala, Jamie, Brown, Thelma, Tolaney, S M, Carey, L, Krop, Ian E., Tayob, Nabihah, Winer, Eric P., Rimawi, Mothaffar, Parsons, Heather A. , Lin, Nancy U., Morganti, Stefania , Ruddy, Kathryn J. , Heiling, Hillary , Rozenblit, Mariya , Stoeckle, James Hart , Pradhan, Deepti , Carey, Lisa A. , Krop, Ian E. , Tayob, Nabihah , Winer, Eric P. , Rimawi, Mothaffar, Lin, Nancy U.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps1147 Get It

TPS1147 Background: Due to dramatic improvements in neoadjuvant and adjuvant HER2-directed therapy (tx), most patients (pts) with early HER2+ breast cancer are cured. As a result, over half of pts newly diagnosed with HER2+ metastatic breast cancer (MBC) now present with de novo stage IV disease. Anti-HER2 tx has also significantly extended survival for pts with HER2+ MBC, with a subgroup of exceptional responders alive many years (yrs) after diagnosis. However, the paradigm for HER2+ MBC remains non-curative, and pts receive tx indefinitely with significant toxicities and costs. The SAPPHO study is investigating whether an intensification approach of sequential, non-cross resistant anti-HER2 tx followed by tx discontinuation is associated with long-term disease control in pts with HER2+ MBC. Methods: SAPPHO is an open-label, phase II, single-arm trial testing a sequential regimen of non-cross resistant, HER2-targeted tx with curative intent in pts with de novo HER2+ MBC. Eligible pts must have biopsy-proven, de novo MBC with high HER2 expression (3+ by immunohistochemistry). Pts with brain metastases are eligible upon receipt of local tx. Treatment consists of an induction regimen (trastuzumab-pertuzumab-taxane [THP] x 4 cycles, followed by trastuzumab deruxtecan [TDXd] x 6 cycles, followed by trastuzumab emtansine [TDM1]-tucatinib x 4 cycles), followed by a maintenance regimen (HP-tucatinib for 1 yr). Given results from DESTINY-Breast09, the sequence of TDXd-P x 6 cycles followed by THP x 4 followed by TDM1-tucatinib x 4 can be chosen as alternative induction tx per investigator and patient choice. Pts who remain progression-free after completing maintenance will stop all anti-HER2 tx. Endocrine tx will be continued for pts with hormone receptor+/HER2+ tumors. Tumor specimens from breast and a metastatic site are collected at baseline and the end of induction. Serial plasma samples for ctDNA analysis are collected at baseline, during treatment, and during follow-up. The primary endpoint is the probability of being progression-free and off anti-HER2 tx 4 yrs from the start of induction. With a sample size of 72 pts, the study is designed to have 91% power to reject the null hypothesis that the probability of being off anti-HER2 tx and progression-free is less than 24%, with an alternative hypothesis of 40%. Key secondary endpoints are overall survival, overall response rate by modified RECIST 1.1 after induction, and safety. Correlative endpoints include the relationship between ctDNA dynamics and outcomes. Patient-reported outcomes will be analyzed, including quality of life, illness intrusiveness, financial toxicity, anxiety, distress about cancer progression, perception of benefit and risk of progression. SAPPHO began enrollment in Q3 2024, and the study is open at 4 US sites within the Translational Breast Cancer Research Consortium (NCT05721248). Clinical trial information: NCT05721248 .
Clinical factors driving use of RET inhibitor pralsetinib and associated real-world outcomes in RET fusion–positive NSCLC: A retrospective chart review.
Evangelist, Makenzi Colleen, Mansfield, Aaron Scott, Garcia, Christine A., Subbiah, Vivek, Papademetriou, Eros , Thomassen, Amber , Sheppard, Aaron, Mansfield, Aaron S. , Garcia, Christine A. , Subbiah, Vivek

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e20731 Get It

e20731 Background: Selective RET (REarranged during Transfection) inhibitors (RETi) have become standard treatment for RET fusion-positive non-small cell lung cancer ( RET + NSCLC), which represent 1–2% of NSCLC cases. Clinical factors that drive front-line versus later-line RETi use and outcomes are not well understood. This retrospective chart review evaluates physician decision drivers alongside real-world effectiveness and safety for pralsetinib (PRAL) in RET + NSCLC. Methods: A retrospective chart review was conducted via a standardized web-based form among US oncologists treating advanced RET + NSCLC. Eligible patients initiated PRAL for RET + NSCLC between October 2020 and December 2024. Data gathered included physician treatment considerations, patient baseline characteristics, and efficacy outcomes. Results: Eighty-two charts from patients who received PRAL as their first (index) RETi were collected from 43 physicians across both academic (41.9%) and community (58.1%) sites. Of the 82 patients, 51.2% received PRAL front line (1L) and 31.7% in the second line (2L). From a predefined list, physicians most often cited comorbidities (36.6%) and ECOG performance status (31.7%) as clinical factors when considering index PRAL therapy and efficacy profile (56.1%), followed by intracranial activity (24.4%) and hypersensitivity to immuno-oncology agents (24.4%) as therapy-related considerations. Although not a primary therapy selection driver, in 13 patients with safety as a consideration, 6 (46.2%) had myelosuppression noted as a concern for index PRAL treatment. RET + NSCLC patients treated in the 1L setting with PRAL had an overall response rate (ORR) of 73.8% (14 CR; 17 PR). For 2L line PRAL, the ORR was 61.5% (1 CR; 15 PR). Anemia (17.1%), diarrhea (13.4%), and constipation (13.4%) were the most frequently reported adverse events (AE). Discontinuation was mainly due to loss of/no response (80.6%), insurance (16.1%), and AEs (3.2%). The single PRAL patient that discontinued due to an AE had edema. There were an additional 7 patients that switched to PRAL due to an AE on a different RETi. The post-switch ORR was 57.1% (4/7); of these patients, 3 maintained their previous response and 1 improved their response. Conclusions: In this retrospective chart review, pralsetinib was used across treatment lines with high real-world response rates, consistent with results from the ARROW trial. Treatment selection was influenced by specific clinical factors including patient comorbidities, ECOG performance status, and safety concerns, with AE-driven switching uncommon yet associated with continued responses.
Impact of anemia on real-world outcomes in myelofibrosis: A propensity-matched analysis.
Chandani, Kanishka Uttam, Thukral, Jatin, Shah, Riya, Tajiknia, Vida , Moudgil, Pyush, Gopu, Sooraj Srirangadhamu , Thukral, Nikhil, Lussier, Amanda, Kondapally, Apoorva, Salunke, Juhi R., Yanamaladoddi, Vishnu, Khan, Muhammad Ali, Ilyas, Usman , Monick, Sarah, Palmer, Jeanne , Thukral, Jatin, Sharma, Ashish , Salunke, Juhi , Yanamaladoddi, Vishnu R. , Nadeem, Ahmed

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e18609 Get It

e18609 Background: Anemia is a frequent complication of myelofibrosis (MF) and is embedded in widely used prognostic systems, yet contemporary real-world estimates of its association with long-term survival and leukemic transformation remain limited. We evaluated the impact of baseline anemia (hemoglobin [Hb] <10 g/dL) on overall survival (OS) and risk of transformation to acute myeloid leukemia (AML) in adults with MF. Methods: We performed a retrospective cohort study using the TriNetX Research Network, identifying adults (≥18 years) with myelofibrosis and stratifying them by anemia status at index (Hb <10 g/dL). Patients with the outcome of interest prior to each analytic window were excluded. To minimize confounding, cohorts were 1:1 propensity score–matched using nearest-neighbor matching with a caliper of 0.1 pooled standard deviations of the logit of the propensity score, adjusting for demographic factors, comorbidities, iron supplementation, leukocyte count, and platelet count. Balance was assessed using standardized mean differences <0.1. The primary outcome was all-cause mortality and the secondary outcome was transformation to AML, assessed at 1, 3, and 5 years. Risk estimates were calculated, and survival analyses were performed using Kaplan–Meier curves and Cox proportional hazards models, with statistical significance defined as a two-sided p<0.05. Results: After matching, 18,504 patients with MF were identified, of which 51.6% were females and 48.3% were males. The mortality rate in patients with anemia was higher than in those without at years 1, 3, and 5: 21.4%, 33.2%, and 39%, respectively, versus 5.4%, 12%, and 16.9%, respectively. The prevalence of transformation to AML was also higher in patients with anemia at 3.7%, 4.9%, and 5.3% at years 1, 3, and 5, respectively, versus 0.1%, 0.3%, and 0.4% in patients without anemia at those same time points. The HR for mortality in MF patients with anemia when compared to those without anemia at years 1, 3, 5 was statistically significant at 4.57 (95% CI 4.14-5.05, log-rank p<0.01), 3.51 (95% CI 3.28-3.76, log-rank p<0.01), and 3.04 (95% CI 2.87-3.23, log-rank p<0.01) respectively. The HR for transformation to AML in patients with MF with anemia versus those without anemia was statistically significant at years 1, 3 and 5, with HRs of 34.96 (95% CI 19.17-63.75, log-rank p<0.01) 20.75 (95% CI 13.97-30.83, log-rank p<0.01) and 17.07 (95% CI 12.11-24.07, log-rank p<0.01), respectively. Conclusions: In this large, propensity-matched real-world EHR analysis, baseline Hb <10 g/dL was associated with substantially worse OS and a markedly higher risk of AML transformation through 5 years. These findings support anemia as a pragmatic risk marker to inform risk-adapted monitoring, supportive care, and therapeutic decision-making in MF.